We provide high-quality data for early compound screening and lead optimization making use of our automated patch-clamp platforms. Our assays account for special features of the respective ion channel targets and, at the same time, address specific demands of our customers. Close contact with our customers is the secret to ChanPharm's success.
Screening of large substance libraries is performed using automated high throughput automated patch-clamp platforms (SyncroPatch and Patchliner). Upon request studies on the mechanism of action of potential lead structures or drug candidates can be performed with manual patch-clamp. Depending on project requirements, ion channel screening includes selectivity profiling, cardiac safety assessment and neurotoxicity evaluation at any stage.
Learn More
Advanced cardiac safety testing using human iPSC-derived cardiomyocytes and CiPA-compliant assays. Our comprehensive assessment includes hERG screening, multi-channel cardiac panels, and in silico modeling to predict pro-arrhythmic risk and support regulatory submissions.
Learn More
Our microfluidic device attaches free-floating 3D spheroids and organoids — cardiospheres, cardioids and neurospheres — to conventional planar multielectrode arrays, enabling stable field-potential measurements with simultaneous imaging. Published in Lab on a Chip and featured on its front cover.
Your contract research organization (CRO) offering compound screening and selectivity profiling for a broad range of ion channels.
We are proud to contribute to the field of ion channel research for more than 30 years. We are experts in developing new channel assays that address the individual demands of our clients on point.
CEO: Dr. Steffen Hering